Clinical CollaborationThe recent drug supply agreement with Roche will supply atezolizumab for the upcoming Phase 3 study, providing a significant cost savings for the company.
EarningsTempest posted EPS of ($3.16), which was better than both the analyst's estimate and the consensus estimate.
Regulatory ProgressTempest recently held a successful EOP2 meeting with the FDA, reaching a broad agreement on the Phase 3 study plan, including dose schedule and primary endpoint.